DeepMed Research

ProKidney, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $1.8B

Website

Clinical Trials

Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product

Conditions: Diabetic Kidney Disease
Chronic Kidney Disease

Interventions: Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2025-01-24

Last Posted Date: 2025-01-24

Lead Sponsor: Prokidney

Target Recruit Count: 50

Registration Number: NCT06790498

Locations: 🇺🇸
Boise Kidney & Hypertension Institute, Meridian, Idaho, United States

A Long-Term Follow-Up Study of Participants Exposed to REACT

Recruiting

Conditions: Diabetic Kidney Disease
Chronic Kidney Diseases

Interventions: Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2023-06-26

Last Posted Date: 2024-02-05

Lead Sponsor: Prokidney

Target Recruit Count: 80

Registration Number: NCT05918523

Locations: 🇺🇸
Boise Kidney & Hypertension Institute, Meridian, Idaho, United States

A Study of Participants With Chronic Kidney Disease Previously Treated With REACT

Phase 1

Terminated

Conditions: CAKUT
Chronic Kidney Diseases
Diabetic Kidney Disease

Interventions: Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2023-01-23

Last Posted Date: 2025-02-28

Lead Sponsor: Prokidney

Target Recruit Count: 1

Registration Number: NCT05694169

Locations: 🇺🇸
Boise kidney and Hypertension Institute, Boise, Idaho, United States

A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease

Phase 3

Recruiting

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Diseases

Interventions: Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

First Posted Date: 2022-03-18

Last Posted Date: 2024-07-26

Lead Sponsor: Prokidney

Target Recruit Count: 600

Registration Number: NCT05286853

Locations: 🇪🇸
IMIM Hospital del Mar Medical Research Institute, Barcelona, Spain
🇪🇸
Hospital Universitario Vall D'Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Phase 3

Recruiting

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Diseases

Interventions: Procedure: Sham Comparator
Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2021-10-29

Last Posted Date: 2025-04-10

Lead Sponsor: Prokidney

Target Recruit Count: 685

Registration Number: NCT05099770

Locations: 🇺🇸
Paradise Clinical Research Group LLC, Glendora, California, United States
🇺🇸
Medicine and Nephrology Associates, Los Alamitos, California, United States
🇺🇸
Academic Medical Research Institute, Los Angeles, California, United States

and more 63 locations

Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Phase 2

Active, not recruiting

Conditions: Chronic Kidney Diseases
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions: Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2021-08-24

Last Posted Date: 2024-01-12

Lead Sponsor: Prokidney

Target Recruit Count: 53

Registration Number: NCT05018416

Locations: 🇺🇸
Nephrology Associates, Newark, Delaware, United States
🇺🇸
Nephrology and Hypertension Associates Ltd - Frenova, Tupelo, Mississippi, United States
🇺🇸
Kidney Associates of Colorado, P.C. - Frenova, Denver, Colorado, United States

and more 2 locations

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

Phase 1

Completed

Conditions: Chronic Kidney Disease
Congenital Anomalies of Kidney and Urinary Tract

Interventions: Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2019-10-04

Last Posted Date: 2023-12-21

Lead Sponsor: Prokidney

Target Recruit Count: 6

Registration Number: NCT04115345

Locations: 🇺🇸
Hackensack Meridian Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Mt. Sinai Hospital, New York, New York, United States

and more 2 locations

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions: Biological: Renal Autologous Cell Therapy (REACT)

First Posted Date: 2017-09-01

Last Posted Date: 2025-03-24

Lead Sponsor: Prokidney

Target Recruit Count: 10

Registration Number: NCT03270956

Locations: 🇺🇸
University of Arizona [WITHDRAWN], Tucson, Arizona, United States
🇺🇸
Boise Kidney & Hypertension Institute, Boise, Idaho, United States
🇺🇸
University of North Carolina- Chapel Hill, Chapel Hill, North Carolina, United States

and more 1 locations

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions: Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Renal Biopsy

First Posted Date: 2016-07-19

Last Posted Date: 2024-10-30

Lead Sponsor: Prokidney

Target Recruit Count: 83

Registration Number: NCT02836574

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Lehigh Valley Health Network, Allentown, Pennsylvania, United States

and more 13 locations

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

Phase 2

Terminated

Conditions: Chronic Kidney Disease
Type 2 Diabetes

Interventions: Biological: Neo-Kidney Augment

First Posted Date: 2015-08-17

Last Posted Date: 2021-04-23

Lead Sponsor: Prokidney

Target Recruit Count: 1

Registration Number: NCT02525263

Locations: 🇺🇸
University of North Carolina- Chapel Hill, Chapel Hill, North Carolina, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy